Cellectar Biosciences announced today its initiation of a Phase II clinical study of CLR 131 in patients with multiple myeloma and other hemotologic malignancies.

According to a release, the study will take place in up to 15 centers in the United States for patients with a variety of orphan-designated relapse or refractory hematologic cancers. Read the full story here.